AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 106 min read$HIMS

Hims & Hers Health (NYSE:HIMS) Exceeds Q2 CY2026 Expectations But Stock Drops

Hims & Hers Health (NYSE:HIMS) reported Q2 CY2026 revenue of $753.2 million, up 38.2% year on year and 7.8% above Wall Street estimates. Management guided next-quarter revenue to $890 million at the midpoint, 12.4% above expectations. GAAP EPS was -$0.37, and the stock fell 5.3% to $30.21 after the release.

Original reporting
financialcontent.com
Published Aug 10, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Hims & Hers Health (NYSE:HIMS) Exceeds Q2 CY2026 Expectations But Stock Drops — source image
Source · financialcontent.com
Decision brief

The 30-second read

$HIMSNeutralMed
01

Why it matters

The article frames Q2 as a revenue upside story with supportive next-quarter revenue guidance, while profitability signals remain mixed due to a GAAP EPS miss and weaker EBITDA guidance.

02

Market read

Traders are likely repricing near-term growth expectations while debating whether margin pressure is temporary or structural.

03

What to watch

Customer growth and spend per customer are discussed, but the article does not quantify marketing intensity or cohort retention, which could explain margin pressure.

Relevance 8/10Novelty 7/10Timing: after-hours/next-session reaction to Q2 results and next-quarter guidance

Background

Hims & Hers is a consumer-focused telehealth platform connecting patients to providers for prescriptions and wellness products.

Company-level read

Ticker impact

$HIMSNeutralMedium confidence
Context

Hims & Hers reported Q2 CY2026 revenue of $753.2M (+38.2% YoY) and guided next-quarter revenue to $890M midpoint, above expectations.

Expected impact

Near-term volatility likely persists as traders weigh revenue upside against profitability and EBITDA concerns.

Evidence & confidence

The text provides concrete Q2 results, next-quarter revenue guidance, and notes EPS missed and EBITDA guidance fell short, plus a same-day drop of 5.3% to $30.21.

Market effects

Sector

Telehealth peers may see read-across on demand durability and monetization, but profitability remains a key swing factor.

Regional

No specific regional spillover mentioned beyond US-listed sentiment.

Global

No explicit global catalyst or cross-border dependency described.

Counterpoint

What could challenge this read

The revenue beat and stronger-than-expected next-quarter midpoint could outweigh the EPS/EBITDA misses if margins stabilize in subsequent quarters.

Key entities

  • company
    Hims & Hers Health

    Telehealth company reporting Q2 CY2026 results and next-quarter revenue guidance.

Read at source← All news

Related articles

AUG 10
$PHigh

After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK

After-hours movers followed a slightly lower Wall Street close. Everpure (P) rose 8% on a design win and supply agreement with a second hyperscaler. Riot Platforms (RIOT) gained 10% on a 20-year, 191 MW data center lease and Q2 revenue of $174.2M. Babcock & Wilcox (BW) jumped 27% on Q2 EPS $0.07 and revenue $319.7M. Rocket Lab (RKLB) fell 1% despite $234.1M Q2 revenue and Q3 guidance. Hims (HIMS) dropped 2% on wider Q2 loss. Upwork (UPWK) fell 17% on weak guidance.

investing.com6 min
AUG 10
$HIMSMedAI 8/10

Why is Hims & Hers Health stock sliding today?

Hims & Hers Health shares fell about 1.5% in after-hours after Q2 2026 results. Revenue rose to $753M (+38% YoY) but EPS was a loss of -$0.37 versus -$0.05 expected, tied to gross margin contracting 12 points from a shift from compounded to branded GLP-1. The company raised FY2026 revenue to $3.1B-$3.3B and Q3 guidance to $880M-$900M, but legal and regulatory overhangs and softer GLP-1 billing weighed.

investing.com6 min
AUG 10
$HIMSMed

Live: Will Hims & Hers Rebound After Tonight’s Q2 Earnings?

Hims & Hers Health (HIMS) is set to report Q2 FY2026 results after the bell Aug 10. The article says Q1 gross margin fell to 65% and net loss was $92.11M on $608.10M revenue. For Q2, it cites guidance of $680M to $700M revenue and $35M to $55M adjusted EBITDA, with a Novo Nordisk Wegovy shipment figure of 125,000 units in six weeks.

247wallst.com6 min
AUG 7
$HIMSHighAI 9/10

FTC Sues Hims & Hers Over Health Privacy and Billing Practices

The U.S. FTC sued telehealth company Hims & Hers, joined by California and Utah, alleging it shared consumers’ private health data with ad platforms owned by Meta and Snap and billed some customers for prescriptions without meaningful consultation. The FTC also alleges unclear refill and subscription cancellation practices. Hims said its privacy policy lets patients choose data use; its stock fell nearly 12% on Wednesday.

neurologyadvisor.com6 min